The effect of ibustrin on early aortocoronary bypass patency

Area of Science:

• Cardiovascular Surgery
• Pharmacology
• Clinical Trials

Background:

• Early thrombosis is a significant risk for low-flow aortocoronary bypasses.
• Maintaining bypass patency is crucial for patient outcomes.

Purpose of the Study:

• To compare the efficacy of aspirin (ASA) and dipyridamole with Ibustrin in maintaining early patency of low-flow aortocoronary bypasses.
• To assess the safety profile of Ibustrin in this patient population.

Main Methods:

• A randomized study involving 49 patients with high-risk bypasses (flow ≤ 40 ml/min).
• Comparison of bypass occlusion rates between ASA/dipyridamole group and Ibustrin group via postoperative angiography (7-10 days).

Main Results:

• Bypass occlusion rates were 28.2% (11/39) for ASA/dipyridamole and 25.8% (8/31) for Ibustrin.
• No statistically significant difference in early patency rates was observed between the two treatment groups.
• Ibustrin administration was not associated with any reported side effects.

Conclusions:

• Ibustrin is as effective as aspirin and dipyridamole in improving early aortocoronary bypass patency.
• Ibustrin represents a safe and effective alternative for preventing early bypass thrombosis in high-risk patients.